50 Participants Needed

Sildenafil for Vascular Disease

OS
LD
Overseen ByLorenzo D'Angelo, MD
Approved in 4 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

Contemporary left ventricular assist device (LVAD) therapy improves survival during advanced heart failure but vascular aging develops rapidly leading to major adverse events including stroke and bleeding in nearly half of patients. In this study, the study team aims to investigate whether sildenafil pharmacotherapy, which has anti-fibrotic effects, can reduce vascular aging during LVAD support. An aim of this study is to compare changes in small blood vessels in the gastrointestinal tract between participants receiving sildenafil or placebo. Video capsule endoscopy (VCE) will be used to assess these changes in small blood vessels.

Do I need to stop my current medications for the trial?

If you are taking any nitric oxide (NO) donor medications, you will need to stop them to participate in this trial.

Is sildenafil safe for use in humans?

Sildenafil, known by various brand names like Viagra and Revatio, is generally considered safe for most people, but it should not be used with nitrates (medications for chest pain) as this can cause a dangerous drop in blood pressure. Some reports have noted heart-related issues, especially in those with existing heart conditions, so it's important to consult a doctor if you have heart disease.12345

How is the drug sildenafil unique for treating vascular disease?

Sildenafil is unique for treating vascular disease because it not only helps with erectile dysfunction and pulmonary hypertension but also shows promise in protecting the heart from damage due to reduced blood flow and other cardiovascular issues. It works by inhibiting an enzyme called phosphodiesterase-5, which helps relax blood vessels and improve blood flow.46789

What data supports the effectiveness of the drug sildenafil for vascular disease?

Sildenafil, known for treating erectile dysfunction, has shown promise in improving heart health by protecting against heart damage and lowering blood pressure in certain conditions. It is also effective in treating pulmonary arterial hypertension, a type of high blood pressure affecting the lungs.46101112

Who Is on the Research Team?

OS

Omar Saeed, MD

Principal Investigator

Montefiore Medical Center

Are You a Good Fit for This Trial?

This trial is for adults over 18 who are receiving durable left ventricular assist device (LVAD) support and can give informed consent. It's not suitable for those with a pre-existing aortic valve prosthesis or graft, allergy to sildenafil, complete carotid occlusion, or those taking nitric oxide donor medications.

Inclusion Criteria

Durable left ventricular assist device support
Be able to give informed consent
I am over 18 years old.

Exclusion Criteria

History of pre-existing aortic valve prosthesis or an aortic graft
Allergy to sildenafil
I have had a complete blockage in my carotid artery.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive sildenafil or placebo to assess vascular remodeling during LVAD support

180 days
Regular visits for monitoring and assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Sildenafil
Trial Overview The study is testing if sildenafil can slow down vascular aging in patients with LVADs. Vascular aging often leads to strokes and bleeding. Participants will either receive sildenafil or a placebo without knowing which one they're getting.
How Is the Trial Designed?
2Treatment groups
Active Control
Placebo Group
Group I: SildeanfilActive Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Sildenafil is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸
Approved in United States as Viagra for:
🇪🇺
Approved in European Union as Viagra for:
🇺🇸
Approved in United States as Revatio for:
🇨🇦
Approved in Canada as Sildenafil for:
🇯🇵
Approved in Japan as Sildenafil for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Montefiore Medical Center

Lead Sponsor

Trials
468
Recruited
599,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Published Research Related to This Trial

Sildenafil citrate (Viagra) has been prescribed to over 10 million patients and has shown significant improvements in erectile function across various conditions, including diabetes and cardiovascular disease, based on clinical trials.
The medication is generally well-tolerated, with most side effects being mild or moderate and rarely causing patients to stop treatment, indicating its safety in a wide range of patients.
Three-year update of sildenafil citrate (Viagra) efficacy and safety.Sadovsky, R., Miller, T., Moskowitz, M., et al.[2022]
Phosphodiesterase 5 inhibitors, like sildenafil, vardenafil, and tadalafil, effectively treat erectile dysfunction by increasing cGMP levels, which relaxes smooth muscle and can slightly lower blood pressure, but caution is needed when used with nitric oxide donors due to the risk of significant hypotension.
These medications not only help with erectile dysfunction but also show potential in treating pulmonary hypertension and may have cardioprotective effects, making them valuable for patients with cardiovascular risk factors.
Cardiovascular effects of phosphodiesterase 5 inhibitors.Reffelmann, T., Kloner, RA.[2019]
Sildenafil citrate (Revatio) is an effective oral treatment for pulmonary arterial hypertension (PAH), significantly improving exercise capacity compared to placebo in patients with idiopathic PAH and other related conditions.
The treatment was well tolerated and also led to improvements in functional class and hemodynamic parameters, indicating its overall efficacy and safety in managing PAH.
Sildenafil: a review of its use in pulmonary arterial hypertension.Croom, KF., Curran, MP.[2021]

Citations

Three-year update of sildenafil citrate (Viagra) efficacy and safety. [2022]
2.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Cardiovascular effects of phosphodiesterase 5 inhibitors. [2019]
Sildenafil: a review of its use in pulmonary arterial hypertension. [2021]
ALERT: Revatio is another brand name for sildenafil. [2017]
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. [2018]
[Side effects of sildenafil: findings from two years practical experience]. [2015]
Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. [2019]
Cardiovascular safety of sildenafil. [2018]
Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. [2015]
10.United Statespubmed.ncbi.nlm.nih.gov
Vardenafil: a new approach to the treatment of erectile dysfunction. [2019]
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. [2015]
12.United Arab Emiratespubmed.ncbi.nlm.nih.gov
New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is). [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security